Allergic rhinitis is associated with IL-4 and IL-13 polymorphism (97), and dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to inhibit type 2 inflammation such as AR (98, 99). This evidence concerns the gene IL4 and allergic rhinitis.